Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996040295 - MONOCLONAL ANTIBODY FRAGMENT TO HUMAN OVARIAN CANCERS

Publication Number WO/1996/040295
Publication Date 19.12.1996
International Application No. PCT/US1996/009819
International Filing Date 07.06.1996
Chapter 2 Demand Filed 07.01.1997
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 51/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
08Peptides, e.g. proteins
10Antibodies or immunoglobulins; Fragments thereof
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 51/1072
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
1045against animal or human tumor cells or tumor cell determinants
1072the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
C07K 16/3069
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
3069Reproductive system, e.g. ovaria, uterus, testes, prostate
G01N 33/57449
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57407Specifically defined cancers
57449of ovaries
G01N 33/57492
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57484involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
57492involving compounds localized on the membrane of tumor or cancer cells
Applicants
  • SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH [US]/[US] (AllExceptUS)
  • LLOYD, Kenneth, O. [US]/[US] (UsOnly)
  • FEDERICI, Mark, G. [US]/[US] (UsOnly)
  • DIVGI, Chaitanya, R. [IN]/[US] (UsOnly)
  • KOSTAKOGLU, Lale [TR]/[TR] (UsOnly)
Inventors
  • LLOYD, Kenneth, O.
  • FEDERICI, Mark, G.
  • DIVGI, Chaitanya, R.
  • KOSTAKOGLU, Lale
Agents
  • WHITE, John, P.
Priority Data
08/478,19007.06.1995US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MONOCLONAL ANTIBODY FRAGMENT TO HUMAN OVARIAN CANCERS
(FR) FRAGMENT D'ANTICORPS MONOCLONAL DIRIGE CONTRE DES CANCERS DE L'OVAIRE CHEZ LA FEMME
Abstract
(EN)
The biodistribution and pharmacokinetics of intact and F(ab')2 fragments of radiolabeled (125I) monoclonal antibody (Mab) MX-35 and a control mAB were compared in nude mice bearing xenografts of OVCAR-3 human epithelial ovarian cancer. The highest tumor to blood ratio was 12.8 for the F(ab')2 fragment and 1.9 for intact Mab MX-35. Maximum tumor to normal tissue ratios were 64 for fragment and 12.3 for intact antibody. The maximum percent injected dose per gm (%IDg-1) of Mab in tumor was 10.4 % for F(ab')2 fragments and 1.6 % for intact antibody when administered intravenously and 8.2 % for F(ab')2 fragments and 2.3 % for intact MX-35 when injected intraperitoneally. The finding of higher percentage ID g-1 for the fragments is unexpected and is in contrast to other published studies.
(FR)
On a comparé la biodistribution et la pharmacocinétique de fragments intacts et de F(ab')2 d'anticorps monoclonal (Mab) MX-35 radiomarqué (125I) et d'un mAB de contrôle chez des souris nudes porteuses d'hétérogreffes de cancer d'ovaire épithélial de la femme OVCAR-3. Le rapport le plus élevé entre la tumeur et le sang était de 12,8 pour le fragment de F(ab')2 et de 1,9 pour le Mab MX-35 intact. Les rapports maximum entre la tumeur et le tissu normal étaient de 64 pour le fragment et de 12,3 pour l'anticorps intact. Le pourcentage maximum de dose injectée par gm (%ID g -1) de Mab dans la tumeur était de 10,4 % pour les fragments de F(ab')2 et de 1,6 % pour l'anticorps intact, administré par voie intraveineuse, de 8,2 % pour les fragments de F(ab')2 et de 2,3 % pour MX-35 intact, injecté par voie intrapéritonéale. La découverte d'un pourcentage d'ID g -1 plus important pour les fragments est inattendue et contraste avec d'autres études publiées.
Also published as
Latest bibliographic data on file with the International Bureau